FibroBiologics (FBLG) Payables (2022 - 2026)

FibroBiologics (FBLG) has reported Payables for 5 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 81.54% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (down 81.54% YoY), and the FY2025 full-year result was $12.5 million, down 1.2% from the prior year.
• Payables advanced to $1.8 million in Q2 2026 per FBLG's latest filing, from $850000.0 in the prior quarter.
• Across five years, Payables topped out at $12.7 million in Q4 2024 and bottomed at $850000.0 in Q1 2026.
• Historically, Payables has averaged $5.6 million across 5 years, with a median of $4.0 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Payables surged 779.29% in 2024, then plunged 88.29% in 2026.
• Over 5 years, Payables stood at $6.2 million in 2022, then plunged by 76.74% to $1.4 million in 2023, then soared by 779.29% to $12.7 million in 2024, then declined by 1.2% to $12.5 million in 2025, then slumped by 85.48% to $1.8 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.8 million, $850000.0, and $12.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.